Efficacy of aspirin for secondary prevention in patients with peripheral artery disease

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 10, 2009, Pages 1203-1207

  Feldman, Dmitriy N ^a   Moussa, Issam D ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Aspirin; Claudication; Peripheral artery disease; Peripheral vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO;

ARTERY DISEASE; BLEEDING; CARDIOVASCULAR DISEASE; CLAUDICATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MORTALITY; NOTE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW;

EID: 70450040403     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.95     Document Type: Note

References (20)

1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110, 738-743 (2004).
2. Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286, 1317-1324.
3. Weitz JI, Byrne J, Clagett GP et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 94, 3026-3049 (1996). (Pubitemid 26411793)
4. Imparato AM, Kim GE, Davidson T, Crowley JG. Intermittent claudication: its natural course. Surgery 78, 795-799 (1975).
5. Dormandy J, Mahir M, Ascady G et al. Fate of the patient with chronic leg ischaemia: a review article. J. Cardiovasc. Surg. (Torino) 30, 50-57 (1989). (Pubitemid 19080681)
6. Fowkes FG, Murray GD, Butcher I et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300, 197-208 (2008). (Pubitemid 351969304)
7. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aorta): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/ AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113, e463-e654 (2006).
8. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308, 81-106 (1994).
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002).
10. Catalano M, Born G, Peto R; Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J. Intern. Med. 261, 276-284 (2007).
11. Belch J, MacCuish A, Campbell I et al.; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337, a1840 (2008). • The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: the largest trial of aspirin therapy in peripheral artery disease. The trial included asymptomatic patients (ankle-brachial index ≤ 0.99) with diabetes mellitus and showed no benefit for aspirin in the prevention of cardiovascular events.
12. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301, 1909-1919 (2009). •• Meta-analysis of 18 trials demonstrated a nonsignificant reduction with aspirin in the primary outcome of cardiovascular events (nonfatal myocardial infarction, nonfatal stroke or cardiovascular mortality), with a statistically significant reduction in the secondary end point of nonfatal stroke.
13. McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh R. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J. Vasc. Surg. 13, 150-161 (1991).
14. Colwell JA, Bingham SF, Abraira C et al. VA Cooperative study of antiplatelet agents in diabetic patients after amputation for gangrene: unobserved, sudden, and unexpected deaths. J. Diabet. Complications 3, 191-197 (1989).
15. Ogawa H, Nakayama M, Morimoto T et al.; Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with Type 2 diabetes: a randomized controlled trial. JAMA 300, 2134-2141 (2008).
16. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 348, 1329-1339 (1996).
17. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706-1717 (2006).
18. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA; CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur. Heart J. 30, 192-201 (2009).
19. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol. 49, 1982-1988 (2007).
20. Price JF, Stewart MC, Deary IJ et al.; AAA Trialists. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. BMJ 337, A1198 (2008).